Breast Cancer Tops List of Malpractice Claims

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

WASHINGTON--Breast cancer leads the list of diseases for which malpractice claims have been filed in the last decade, according to a study from the Physician Insurers Association of America. Of 117,000 claims filed since 1985, about 2,500 involved breast cancer.

WASHINGTON--Breast cancer leads the list of diseases for whichmalpractice claims have been filed in the last decade, accordingto a study from the Physician Insurers Association of America.Of 117,000 claims filed since 1985, about 2,500 involved breastcancer.

The association stressed that this number is small compared withthe estimated 1.5 million women who received a breast cancer diagnosisduring that period.

In an analysis of 487 delay in diagnosis claims, the average delaywas 14 months; 91% of these patients were under age 50. Although60% of these women found a lump by self-examination, in 35% ofcases, the "physical findings failed to impress the physician,"the study said, and this was the most common reason for delay.The second leading cause was failure to follow up on physicalexams and inconclusive mammograms.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content